$106.59
1.02% yesterday
Nasdaq, May 01, 10:00 pm CET
ISIN
US64125C1099
Symbol
NBIX

Neurocrine Biosciences, Inc. Stock price

$106.59
-0.41 0.38% 1M
-15.62 12.78% 6M
-29.91 21.91% YTD
-36.44 25.48% 1Y
+15.37 16.85% 3Y
+11.00 11.51% 5Y
+71.08 200.17% 10Y
Nasdaq, Closing price Thu, May 01 2025
-1.10 1.02%
ISIN
US64125C1099
Symbol
NBIX
Sector
Industry

Key metrics

Market capitalization $10.55b
Enterprise Value $9.97b
P/E (TTM) P/E ratio 32.39
EV/FCF (TTM) EV/FCF 17.88
EV/Sales (TTM) EV/Sales 4.23
P/S ratio (TTM) P/S ratio 4.48
P/B ratio (TTM) P/B ratio 4.09
Revenue growth (TTM) Revenue growth 24.81%
Revenue (TTM) Revenue $2.36b
EBIT (operating result TTM) EBIT $583.00m
Free Cash Flow (TTM) Free Cash Flow $557.20m
Cash position $1.08b
EPS (TTM) EPS $3.29
P/E forward 26.57
P/S forward 3.98
EV/Sales forward 3.76
Short interest 5.90%
Show more

Is Neurocrine Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,788 stocks worldwide.

Neurocrine Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

23x Buy
85%
4x Hold
15%

Analyst Opinions

27 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

Buy
85%
Hold
15%

Financial data from Neurocrine Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2,355 2,355
25% 25%
100%
- Direct Costs 58 58
0% 0%
2%
2,298 2,298
26% 26%
98%
- Selling and Administrative Expenses 980 980
13% 13%
42%
- Research and Development Expense 708 708
29% 29%
30%
610 610
47% 47%
26%
- Depreciation and Amortization 27 27
27% 27%
1%
EBIT (Operating Income) EBIT 583 583
48% 48%
25%
Net Profit 341 341
37% 37%
14%

In millions USD.

Don't miss a Thing! We will send you all news about Neurocrine Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neurocrine Biosciences, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568 (NBI-'568), an investigational oral muscarinic M4 selective orthosteric agonist, as a potential treatmen...
Neutral
PRNewsWire
one day ago
SAN DIEGO , April 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568, the company's investigational oral muscarinic M4 selective orthosteric agonist, as a potential treatment for schizophrenia. Positive top-line data for the Phase 2 clinical study...
Neutral
PRNewsWire
7 days ago
Post-hoc analysis of higher risk older adults showed substantial and sustained improvements in tardive dyskinesia symptoms with no new treatment-emergent adverse events of clinical concern SAN DIEGO , April 24, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a post-hoc analysis from two 48-week studies, the KINECT® 3 extension and KINECT® 4, demon...
More Neurocrine Biosciences, Inc. News

Company Profile

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Head office United States
CEO Kyle Gano
Employees 1,800
Founded 1992
Website www.neurocrine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today